Evidence map›Paper›PMID 29580219›Full record

ArticleBMC genomics2018

A Sequel to Sanger: amplicon sequencing that scales.

Paul D N Hebert, Thomas W A Braukmann, Sean W J Prosser, Sujeevan Ratnasingham, Jeremy R deWaard, Natalia V Ivanova, Daniel H Janzen, Winnie Hallwachs, Suresh Naik, Jayme E Sones and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 289 citations in OpenAlex.

  1. Article
  2. Constructing a lower-bound estimate of the global number of insect species on a hyperdiverse empirical foundation.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Two new species ofZooKeys · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Paul D N HebertCentre for Biodiversity Genomics, University of Guelph, Guelph, ON, N1G 2W1, Canada. phebert@uoguelph.ca.
Thomas W A BraukmannCentre for Biodiversity Genomics, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Sean W J ProsserCentre for Biodiversity Genomics, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Sujeevan RatnasinghamCentre for Biodiversity Genomics, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Jeremy R deWaardCentre for Biodiversity Genomics, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Natalia V IvanovaCentre for Biodiversity Genomics, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Daniel H JanzenDepartment of Biology, University of Pennsylvania, Philadelphia, PA, 19104-6018, USA.
Winnie HallwachsDepartment of Biology, University of Pennsylvania, Philadelphia, PA, 19104-6018, USA.
Suresh NaikCentre for Biodiversity Genomics, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Jayme E SonesCentre for Biodiversity Genomics, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Evgeny V ZakharovCentre for Biodiversity Genomics, University of Guelph, Guelph, ON, N1G 2W1, Canada.
University of Guelph · CAUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough high-throughput sequencers (HTS) have largely displaced their Sanger counterparts, the short read lengths and high error rates of most platforms constrain their utility for amplicon sequencing. The present study tests the capacity of single molecule, real-time (SMRT) sequencing implemented on the SEQUEL platform to overcome these limitations, employing 658 bp amplicons of the mitochondrial cytochrome c oxidase I gene as a model system.

resultsBy examining templates from more than 5000 species and 20,000 specimens, the performance of SMRT sequencing was tested with amplicons showing wide variation in GC composition and varied sequence attributes. SMRT and Sanger sequences were very similar, but SMRT sequencing provided more complete coverage, especially for amplicons with homopolymer tracts. Because it can characterize amplicon pools from 10,000 DNA extracts in a single run, the SEQUEL can reduce greatly reduce sequencing costs in comparison to first (Sanger) and second generation platforms (Illumina, Ion).

conclusionsSMRT analysis generates high-fidelity sequences from amplicons with varying GC content and is resilient to homopolymer tracts. Analytical costs are low, substantially less than those for first or second generation sequencers. When implemented on the SEQUEL platform, SMRT analysis enables massive amplicon characterization because each instrument can recover sequences from more than 5 million DNA extracts a year.

Indexed as

AnimalsArthropodsGenetic VariationHigh-Throughput Nucleotide SequencingPolymerase Chain ReactionSequence Analysis, DNADNA barcodingHomopolymerMitochondrial DNANuclear DNANucleotide compositionPCRPhylogeneticsSMRT sequencing

Identifiers

PMID29580219
PMCPMC5870082
OpenAlexW2949819089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.